Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHA:603139)
China · Delayed Price · Currency is CNY 23.63
+0.70 (3.05%)
Feb 4, 2026, 3:00 PM CST
SHA:603139 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 496 | 544.4 | 664.59 | 487.17 | 441.42 | 412.86 |
Other Revenue | 17.23 | 17.23 | 8.37 | 4.35 | 1.33 | 1.21 |
| 513.23 | 561.63 | 672.96 | 491.51 | 442.76 | 414.07 | |
Revenue Growth (YoY) | -15.21% | -16.54% | 36.92% | 11.01% | 6.93% | -4.02% |
Cost of Revenue | 393.35 | 405.9 | 489.21 | 303.02 | 241.87 | 221.41 |
Gross Profit | 119.88 | 155.73 | 183.75 | 188.49 | 200.88 | 192.66 |
Selling, General & Admin | 199.38 | 195.1 | 165.34 | 172.36 | 167.11 | 141.02 |
Research & Development | 8.73 | 8.32 | 10.98 | 12.35 | 10.15 | 10.36 |
Other Operating Expenses | 7.39 | 7.37 | 5.23 | 3.17 | 3.65 | 3.84 |
Operating Expenses | 279.64 | 216.7 | 182.38 | 196.66 | 182.61 | 158.41 |
Operating Income | -159.77 | -60.97 | 1.37 | -8.17 | 18.27 | 34.25 |
Interest Expense | -35.99 | -34.79 | -23.46 | -13.22 | -6.32 | -1.48 |
Interest & Investment Income | - | 2.72 | 5.32 | 5.62 | 17.21 | 8.59 |
Other Non Operating Income (Expenses) | -1.98 | -1.28 | -4.02 | -1.23 | -1.78 | 0.19 |
EBT Excluding Unusual Items | -197.74 | -94.32 | -20.78 | -17 | 27.38 | 41.55 |
Impairment of Goodwill | - | - | - | -4.87 | - | - |
Gain (Loss) on Sale of Investments | -37.15 | -31.15 | -28.74 | -54.83 | 9.47 | - |
Gain (Loss) on Sale of Assets | -1.08 | -1.04 | 0.05 | -6.68 | - | -0.03 |
Asset Writedown | 1.81 | - | -16.86 | - | -0.01 | -0.1 |
Other Unusual Items | 4.88 | 4.97 | 8.38 | 0.63 | 1.75 | 2.13 |
Pretax Income | -229.28 | -121.54 | -57.94 | -82.74 | 38.59 | 43.54 |
Income Tax Expense | -8.17 | -9.54 | -7.17 | -5.96 | 5.59 | 7.09 |
Earnings From Continuing Operations | -221.1 | -112 | -50.78 | -76.78 | 33 | 36.46 |
Minority Interest in Earnings | 37.26 | 22.37 | 24.62 | 13.73 | 3.48 | -2.34 |
Net Income | -183.84 | -89.63 | -26.16 | -63.06 | 36.48 | 34.11 |
Net Income to Common | -183.84 | -89.63 | -26.16 | -63.06 | 36.48 | 34.11 |
Net Income Growth | - | - | - | - | 6.94% | -20.23% |
Shares Outstanding (Basic) | 99 | 100 | 101 | 100 | 99 | 100 |
Shares Outstanding (Diluted) | 99 | 100 | 101 | 100 | 99 | 100 |
Shares Change (YoY) | -0.60% | -1.02% | 0.52% | 1.51% | -1.73% | 0.89% |
EPS (Basic) | -1.86 | -0.90 | -0.26 | -0.63 | 0.37 | 0.34 |
EPS (Diluted) | -1.86 | -0.90 | -0.26 | -0.63 | 0.37 | 0.34 |
EPS Growth | - | - | - | - | 8.82% | -20.93% |
Free Cash Flow | 47.29 | -9.37 | -144.52 | -87.7 | -282.88 | -171.86 |
Free Cash Flow Per Share | 0.48 | -0.09 | -1.44 | -0.88 | -2.87 | -1.71 |
Dividend Per Share | - | - | - | - | 0.074 | 0.070 |
Dividend Growth | - | - | - | - | 5.71% | -18.61% |
Gross Margin | 23.36% | 27.73% | 27.30% | 38.35% | 45.37% | 46.53% |
Operating Margin | -31.13% | -10.86% | 0.20% | -1.66% | 4.13% | 8.27% |
Profit Margin | -35.82% | -15.96% | -3.89% | -12.83% | 8.24% | 8.24% |
Free Cash Flow Margin | 9.21% | -1.67% | -21.48% | -17.84% | -63.89% | -41.51% |
EBITDA | -84.52 | -2.19 | 38.21 | 17.18 | 34.64 | 46.21 |
EBITDA Margin | -16.47% | -0.39% | 5.68% | 3.50% | 7.82% | 11.16% |
D&A For EBITDA | 75.24 | 58.78 | 36.83 | 25.34 | 16.37 | 11.96 |
EBIT | -159.77 | -60.97 | 1.37 | -8.17 | 18.27 | 34.25 |
EBIT Margin | -31.13% | -10.86% | 0.20% | -1.66% | 4.13% | 8.27% |
Effective Tax Rate | - | - | - | - | 14.49% | 16.28% |
Revenue as Reported | 513.23 | 561.63 | 672.96 | 491.51 | 442.76 | 414.07 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.